|
|
|
|
|
|
Sponsors and Collaborators: |
University of Minnesota GlaxoSmithKline |
Information provided by: | University of Minnesota |
ClinicalTrials.gov Identifier: | NCT00553969 |
This study will examine the individual and combined effects of Coreg CR and lisinopril, on cardiovascular health as measured by Rasmussen Disease Score (RDS) in a blinded, placebo controlled comparison over a 9-month study period. Patients to be randomized will have pre-hypertensive blood pressures that do not require anti-hypertensive therapy and at least one additional cardiovascular risk factor.
Condition | Intervention | Phase |
Pre-Hypertension |
Drug: carvedilol phosphate Drug: lisinopril Drug: carvedilol phosphate and lisinopril |
Phase I Phase II |
MedlinePlus related topics: | High Blood Pressure |
ChemIDplus related topics: | Lisinopril Carvedilol Carvedilol phosphate |
Study Type: | Interventional |
Study Design: | Treatment, Randomized, Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Factorial Assignment |
Official Title: | Efficacy of Coreg CR and Lisinopril on Markers for Cardiovascular Functional and Structural Disease. DETECT (DEtection and Treatment of Early Cardiovascular Disease Trial) |
Estimated Enrollment: | 100 |
Study Start Date: | November 2007 |
Estimated Study Completion Date: | September 2009 |
Estimated Primary Completion Date: | September 2009 (Final data collection date for primary outcome measure) |
Arms | Assigned Interventions |
1: Experimental
Coreg CR + lisinopril
|
Drug: carvedilol phosphate and lisinopril
carvedilol phosphate = extended release capsules, 20mg once daily for 1 month, 40mg once daily for 8 months; lisinopril= tablets, 10mg once daily for 1 month, 20mg once daily for 8 months
|
2: Experimental
Coreg CR + placebo
|
Drug: carvedilol phosphate
Extended release capsules, 20mg once daily for 1 month, 40mg once daily for 8 months
|
3: Experimental
lisinopril + placebo
|
Drug: lisinopril
tablets, 10mg once daily for 1 month, 20mg once daily for 8 months
|
Ages Eligible for Study: | 19 Years and older |
Genders Eligible for Study: | Both |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
Exclusion Criteria:
Contact: Sara M Saul, PhD | 612-626-5446 | saul@umn.edu |
United States, Minnesota | |||||
University of Minnesota, Variety Club Research Center 102 | Recruiting | ||||
Minneapolis, Minnesota, United States, 55455 | |||||
Contact: Sara M Saul, PhD 612-626-5446 saul@umn.edu |
University of Minnesota |
GlaxoSmithKline |
Principal Investigator: | Jay N Cohn, MD | Professor, University of Minnesota, Cardiology Division |
Responsible Party: | University of Minnesota ( Jay N. Cohn, MD ) |
Study ID Numbers: | 0709M15829 |
First Received: | November 5, 2007 |
Last Updated: | May 22, 2008 |
ClinicalTrials.gov Identifier: | NCT00553969 |
Health Authority: | United States: Institutional Review Board |
|
|
|
|